My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    Some ethical considerations for the "off-label" use of drugs such as Avastin.

    Wong D, Kyle G.

    Br J Ophthalmol. 2006 Oct;90(10):1218-9. Review. No abstract available. PMID: 16980641 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.

    Klein RM, Klein RB.

    Retina. 2007 Nov-Dec;27(9):1163-5. No abstract available. PMID: 18046218 [PubMed - indexed for MEDLINE]Related articles

    3.

    Avastin versus Lucentis: ethical issues.

    Wong HC.

    Retina. 2008 Jul-Aug;28(7):1024-5; author reply 1025. No abstract available. PMID: 18698312 [PubMed - indexed for MEDLINE]Related articles

    4.

    [Treatment of neovascular age-related macular degeneration with bevacizumab]

    Monzón Moreno A.

    Farm Hosp. 2006 Nov-Dec;30(6):387-8. Spanish. No abstract available. PMID: 17298199 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).

    Nagpal M, Nagpal K, Nagpal PN.

    Indian J Ophthalmol. 2007 Nov-Dec;55(6):437-9. Review.PMID: 17951900 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Intravitreal avastin: the low cost alternative to lucentis?

    Rosenfeld PJ.

    Am J Ophthalmol. 2006 Jul;142(1):141-3. No abstract available. PMID: 16815262 [PubMed - indexed for MEDLINE]Related articles

    7.

    Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

    Ziemssen F, Heiduschka P, Schraermeyer U; Tübingen Bevacizumab Study Group.

    Retina. 2007 Oct;27(8):1154-6; author reply 1156-8. No abstract available. PMID: 18040264 [PubMed - indexed for MEDLINE]Related articles

    8.

    Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?

    la Cour M.

    Acta Ophthalmol Scand. 2007 Feb;85(1):2-4. No abstract available. PMID: 17244202 [PubMed - indexed for MEDLINE]Related articles

    9.

    [Age-related macular degeneration: therapeutic hopes]

    Behar-Cohen F, Sennlaub F, Berdugo M.

    Med Sci (Paris). 2007 Feb;23(2):127-9. French. No abstract available. PMID: 17291419 [PubMed - indexed for MEDLINE]Related articles

    10.

    Debate on the various anti-vascular endothelial growth factor drugs.

    Khalili MR, Hosseini H.

    Indian J Ophthalmol. 2008 May-Jun;56(3):255-6; author reply 256. No abstract available. PMID: 18417837 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    New treatments for age-related macular degeneration.

    Avery RL.

    Lancet. 2007 Oct 27;370(9597):1479-80; author reply 1480. No abstract available. PMID: 17964341 [PubMed - indexed for MEDLINE]Related articles

    12.

    Avastin and new treatments for AMD: where are we?

    Freeman WR, Falkenstein I.

    Retina. 2006 Oct;26(8):853-8. Review. No abstract available. PMID: 17031283 [PubMed - indexed for MEDLINE]Related articles

    13.

    Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.

    Kimmelman J.

    Retina. 2007 Nov-Dec;27(9):1166-7. No abstract available. PMID: 18046219 [PubMed - indexed for MEDLINE]Related articles

    14.

    The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration.

    Azad R, Chandra P, Gupta R.

    Indian J Ophthalmol. 2007 Nov-Dec;55(6):441-3. Review.PMID: 17951901 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?

    Bopp S.

    Br J Ophthalmol. 2007 Oct;91(10):1259-60. No abstract available. PMID: 17895411 [PubMed - indexed for MEDLINE]Related articles

    16.

    Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (avastin)--a South African perspective.

    Jansen RM, Gouws C.

    S Afr Med J. 2009 Jun;99(6):446-9.PMID: 19736847 [PubMed - indexed for MEDLINE]Related articles

    17.

    Treatment of macular degeneration--controversy and hope.

    McGimpsey SJ, Gillies MC.

    Br J Ophthalmol. 2008 Mar;92(3):436-7. No abstract available. PMID: 18314407 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series]

    Meyer CH, Helb HM, Eter N.

    Ophthalmologe. 2008 Feb;105(2):125-38, 140-2. Review. German. PMID: 18256841 [PubMed - indexed for MEDLINE]Related articles

    19.

    Tachyphylaxis and bevacizumab.

    Avgikos KN, Horgan SE, Sivaraj RR, Hu K.

    Ophthalmology. 2009 Sep;116(9):1831-2; author reply 1832. No abstract available. PMID: 19729101 [PubMed - indexed for MEDLINE]Related articles

    20.

    Tachyphylaxis and bevacizumab.

    Ziemssen F, Neuhann IM, Voelker M.

    Ophthalmology. 2009 Aug;116(8):1591-2; author reply 1592-3. No abstract available. PMID: 19651319 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity